Alpha 2.0
Login Register
» Articles » PMID: 15523076

Risks and Benefits of Phase 1 Clinical Trials Evaluating New Anticancer Agents: a Case for More Innovation

Overview
Journal JAMA
Publisher American Medical Association
Specialty General Medicine
Date 2004 Nov 4
PMID 15523076
Citations 7
Authors
Eric X Chen
Ian F Tannock
Affiliations
Soon will be listed here.
Citing Articles

SEETrials: Leveraging large language models for safety and efficacy extraction in oncology clinical trials.

Lee K, Paek H, Huang L, Hilton C, Datta S, Higashi J Inform Med Unlocked. 2024; 50.

PMID: 39493413 PMC: 11530223. DOI: 10.1016/j.imu.2024.101589.

Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023.

Guerra M, Alouani E, Hueso T, Ouali K, Danu A, Hollebecque A Eur J Haematol. 2024; 114(1):89-97.

PMID: 39305190 PMC: 11613620. DOI: 10.1111/ejh.14307.

Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology.

Douma J, Buffart L, Sedhom R, Labots M, Menke-van der Houven van Oordt W, Skardhamar M Cancers (Basel). 2021; 13(10).

PMID: 34064995 PMC: 8151105. DOI: 10.3390/cancers13102304.

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Weber J, Levit L, Adamson P, Bruinooge S, Burris 4th H, Carducci M J Clin Oncol. 2014; 33(3):278-84.

PMID: 25512456 PMC: 4516884. DOI: 10.1200/JCO.2014.58.2635.

Lost in migration.

Mack G, Marshall A Nat Biotechnol. 2010; 28(3):214-29.

PMID: 20212481 DOI: 10.1038/nbt0310-214.